Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNAR-4: TTFields + Pembrolizumab in Metastatic NSCLC
NCT06558799Phase 2Terminated
- Sponsor
- NovoCure
- Start
- Oct 2024
- Primary completion
- Feb 2026
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by NovoCure. Primary endpoint: Overall Survival at 16 months. Started Oct 2024; status: terminated.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06558799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558799.